AstraZeneca PLC CEO Pascal Soriot told reporters: * CEO says can't comment on Pfizer, says November 18 investor day will focus on company's progress * CEO says hopes for outcome to DOJ probe into Plato study on Brilinta verysoon * CEO says Almirall respiratory drugs complement Pearl portfolio very well * CEO says in discussions over partnering neuroscience and anti-infectivedrugs, hopes to enter collaborations in H2 * CEO says Russia events may impact company but retail focus should limitdamage * CEO says strongly committed to progressive dividend policy * For more news, please click here
AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. Shares of AZN traded higher by 0.11% or $0.08/share to $73.19. In the past year, the shares have traded as low as $48.53 and as high as $82.68. On average, 4514720 shares of AZN exchange hands on a given day and today's volume is recorded at 3357685.
Source
